SCHEMBL2437486

SCHEMBL2437486

Cn1c(=O)c(C(=O)CCC(=O)O)c(O)c2ccncc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 3/20 0.63
KDM5A P29375 1/20 0.47
HIF1A Q16665 1/20 0.45
RAB9A P51151 5/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 5/20 0.43
NPSR1 Q6W5P4 2/20 0.42
NPC1 O15118 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 7/20 0.41
LMNA P02545 3/20 0.41
TP53 P04637 2/20 0.41
NLRP3 Q96P20 1/20 0.41
ALOX12 P18054 1/20 0.40
PGR P06401 1/20 0.40
HTT P42858 2/20 0.40
USP2 O75604 2/20 0.40
MAPT P10636 2/20 0.40
ADORA3 P0DMS8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2441282 0.82 EGLN1 (0.69) EGLN1RAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL13818070 0.81 ALDH1A1 (0.64) KDM5AHIF1ARAB9ASMN1; SMN2ALDH1A1
SCHEMBL3629411 0.81 EGLN1 (0.43) EGLN1HIF1ARAB9ASMN1; SMN2ALDH1A1
SCHEMBL2578927 0.81 HIF1A (0.67) EGLN1HIF1ARAB9ANPC1MEN1
SCHEMBL12291923 0.79 EGLN1 (0.76) EGLN1HIF1ARAB9AALDH1A1NPC1
SCHEMBL2441228 0.78 EGLN1 (0.58) EGLN1HIF1ARAB9ASMN1; SMN2ALDH1A1
SCHEMBL2435683 0.78 EGLN1 (1.00) EGLN1HIF1ARAB9AALDH1A1NPC1
SCHEMBL2438424 0.78 EGLN1 (0.74) EGLN1HIF1ARAB9AALDH1A1NPC1
SCHEMBL2441366 0.77 EGLN1 (0.56) EGLN1HIF1ARAB9AALDH1A1NPSR1
SCHEMBL2435696 0.76 EGLN1 (0.71) EGLN1HIF1ARAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142509-B1 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP claimed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US claimed
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2011-09-15 US claimed
EP-2142509-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE Amgen, Inc (US) 2010-01-13 EP claimed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US claimed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO claimed
EP-2142509-B1 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2011-09-15 US disclosed
EP-2142509-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE Amgen, Inc (US) 2010-01-13 EP disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase EGLN3, HIF1AN, EGLN2 EGLN1 6/4885KDM5A 180/4885HIF1A 5/4885
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE HIF1AN, EGLN3, EGLN2 EGLN1 6/4885KDM5A 120/4885HIF1A 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.